candesartan/hct actavis 32 mg/12,5 mg tabletten
actavis group ptc ehf - candesartan cilexetil; hydrochlorothiazid -
candesartan/hct actavis 32 mg/25 mg tabletten
actavis group ptc ehf - candesartan cilexetil; hydrochlorothiazid -
candesartan/hct actavis 8 mg/12,5 mg tabletten
actavis group ptc ehf. - candesartan cilexetil; hydrochlorothiazid -
eplerenon actavis 25 mg filmtabletten
actavis group ptc ehf. - eplerenon -
eplerenon actavis 50 mg filmtabletten
actavis group ptc ehf. - eplerenon -
ramipril/hct actavis 5 mg/12,5 mg tabletten
actavis group ptc ehf - hydrochlorothiazid; ramipril - ramipril und diuretika
desloratadine actavis
actavis group ptc ehf - desloratadin - rhinitis, allergic, perennial; urticaria; rhinitis, allergic, seasonal - antihistaminika zur systemischen verwendung, - behandlung von allergischer rhinitis und urtikaria.
famciclovir actavis 125 mg filmtabletten
actavis group ptc ehf. - famciclovir - famciclovir
famciclovir actavis 500 mg filmtabletten
actavis group ptc ehf. - famciclovir - famciclovir
imatinib actavis
actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. die wirkung von imatinib auf das ergebnis der knochenmark-transplantation ist nicht bestimmt worden. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. die erfahrungen mit imatinib bei patienten mit mds/mpd im zusammenhang mit pdgfr-gen re-arrangements ist sehr begrenzt. es gibt keine kontrollierten studien zeigen einen klinischen nutzen oder erhöhte überlebenschancen für diese krankheiten.